2024-10-18 - Analysis Report
## Pfizer Inc. (PFE) Stock Analysis Report

This report analyzes Pfizer Inc. (PFE) stock based on provided data and external sources. 

**1. Performance vs. S&P 500 (VOO)**

Pfizer Inc. is a pharmaceutical company developing and manufacturing medicines and vaccines.  Its stock performance has lagged behind the S&P 500 significantly. 

* **Cumulative Return (PFE):** -10.74%
* **Cumulative Return (VOO):** 136.93%
* **Relative Divergence (Current):** -147.67 (meaning PFE is currently 147.67% below the S&P 500)
* **Relative Divergence (Max):** 14.44
* **Relative Divergence (Min):** -147.67
* **Relative Divergence (Current):** 1.22 (meaning PFE is currently at the 1.22nd percentile of its historical relative divergence against the S&P 500)

**2. Recent Price Movement**

* **Closing Price:** 29.67
* **5-Day Moving Average:** 29.34
* **20-Day Moving Average:** 29.17
* **60-Day Moving Average:** 29.26

The stock is trading slightly above its recent moving averages, indicating a potential short-term uptrend.

**3. Technical Indicators**

* **RSI:** 57.54 (Neutral; suggesting neither overbought nor oversold conditions)
* **PPO:** 0.19 (Positive; indicating potential bullish momentum)
* **Delta_Previous_Relative_Divergence:** -1.32 (Negative; indicates recent short-term price weakness)
* **Expected Return:** 0.0% (over 5 years, relative to S&P 500, based on provided data). 

**4. Recent Earnings and Outlook**

| Date        | EPS | Expected EPS |
|-------------|-----|--------------|
| 2024-07-30 | 0.6  | 0.458        |
| 2024-05-01 | 0.82 | 0.516        |
| 2024-01-30 | 0.1  | -0.19        |
| 2023-10-31 | -0.17 | -0.32        |
| 2023-08-01 | 0.67 | 0.56        |

The most recent earnings (2024-07-30) beat expectations by a significant margin, suggesting strong performance. This positive earnings surprise could potentially drive the stock price up.

**5. News and Recent Issues**

* **Recent Market Outlook:** Pfizer continues to navigate the post-pandemic market and face challenges in maintaining growth for its COVID-19 vaccines. However, it is actively pursuing new treatment and preventative solutions in other areas like oncology and rare diseases. 
* **Analyst Opinions:** Many analysts remain optimistic about Pfizer's long-term prospects, citing its strong pipeline of new drugs and its robust financial position. They anticipate continued growth and believe the stock is undervalued. 
* **Performance Highlights:** Pfizer has achieved impressive sales growth in recent years driven by COVID-19 related products. However, the company is facing intense competition in its key markets, leading to some margin pressure.

**6. Overall Analysis**

Pfizer has faced significant headwinds in the past year, reflected in its underperformance compared to the broader market. However, recent earnings results have shown a positive trend, with a strong beat in the most recent quarter.  The company is well-positioned for future growth due to its robust drug pipeline and solid financial position. While the stock has been lagging, its strong fundamentals and analyst optimism suggest a potential for upside. 

**7. Recommendations**

* **Investors with a longer-term horizon might consider adding Pfizer to their portfolios due to its strong growth potential and the potential for positive surprises.**
* **It is important to note that the stock's recent performance has been volatile. Investors should carefully consider their risk tolerance before investing.**
* **Monitoring future earnings releases and news developments will be crucial for investors to assess the stock's future performance.** 

This report provides a basic overview of Pfizer's current state based on the provided data. For a comprehensive investment decision, it is crucial to perform further research and consider additional factors like industry trends and regulatory landscapes.
